Chronic Heart Failure Epidemiology Forecasts, 2020-2034 With Focus On United States, Germany, France, Italy, Spain, United Kingdom, And Japan

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Nov. 27, 2024 (GLOBE NEWSWIRE) -- The "Chronic Heart Failure - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of Underactive Bladder (UAB), historical and forecasted epidemiology of Underactive Bladder (UAB) in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The analyst's analyst projects that the Total Diagnosed Prevalent Cases of Underactive Bladder (UAB) in the 7MM were ~ 1.79 million in 2023 and these cases are going to increase during the forecast period (2024-2034). This increase in growth can be attributed to growing awareness, ultimately leading to an increase in the diagnosed prevalence of UAB.

According to the publisher's analysis, approximately 36% of the Total Diagnosed Prevalent Cases of Underactive Bladder (UAB) in the 7MM were in the United States. Our estimations indicate that in 2023, the EU4 and the UK collectively represented nearly 915 thousand diagnosed prevalent cases of UAB.

Gender-specific diagnosed prevalent cases of Underactive Bladder (UAB) showed that males were more affected by UAB than females in the 7MM in 2023. Men are more frequently affected by UAB due to a higher prevalence of prostate-related issues, such as benign prostatic hyperplasia, which can obstruct bladder outflow and impair bladder muscle function.

According to the analyst's model, diagnosed UAB cases in Japan for 2023 were classified into Detrusor Underactivity, Detrusor Hyperactivity with Impaired Contractility (DHIC), and Acontractile Detrusor (AcD). Detrusor Underactivity accounted for the majority with around 132 thousand cases, while AcD represented approximately 60 thousand cases.

The analyst's analysis shows that, in 2023, the neurogenic subtype represented the highest proportion of diagnosed underactive bladder cases in the US, with approximately 385 thousand cases. This was followed by idiopathic cases at 132 thousand, other unspecified cases at 83 thousand, and myogenic cases at 42 thousand.

Scope of the Report

• The report covers a segment of executive summary, descriptive overview of Underactive Bladder (UAB) explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Underactive Bladder (UAB) Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Prevalent Cases of LUTS - Moderate to Severe
• Total Diagnosed Prevalent Cases of Underactive Bladder (UAB)
• Gender-specific Diagnosed Prevalent Cases of Underactive Bladder (UAB)
• Classification-specific Diagnosed Prevalent Cases of Underactive Bladder (UAB)
• Etiology-specific Diagnosed Prevalent Cases of Underactive Bladder (UAB)

Underactive Bladder (UAB) Report Key Strengths

• 11 years Forecast
• The 7MM Coverage
• UAB Epidemiology Segmentation

Underactive Bladder (UAB) Report Assessment

• Current Diagnostic Practices Patient Segmentation

Epidemiology Insights

• What are the disease risk, burdens, and unmet needs of Underactive Bladder (UAB)? What will be the growth opportunities across the 7MM concerning the patient population of Underactive Bladder (UAB)?
• What is the historical and forecasted Underactive Bladder (UAB) patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Why is the diagnosed prevalent cases of UAB in Japan lower than the US?
• Which country has a high patient share for UAB?

Key Topics Covered:
1. Key Insights
2. Report Introduction
3. Executive Summary of Chf
4. Chf Overview at a Glance
4.1. Patient Share (%) Distribution of Chf in 2020 in the 7MM
4.2. Patient Share (%) Distribution of Chf in 2034 in the 7MM
5. Epidemiology Forecast Methodology
6. Disease Background and Overview
6.1. Introduction
6.2. Causes of Chf
6.3. Signs and Symptoms
6.4. Stages of Heart Failure
6.5. Classification of Heart Failure
6.6. Common Pathophysiologic Mechanisms in Heart Failure
6.7. Biomarkers for the Heart Failure
6.8. Diagnosis
6.8.1. Differential Diagnosis
7. Diagnostic Guidelines
8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Assumptions and Rationale
8.3. Total Diagnosed Prevalent Cases of Heart Failure in the 7MM
8.4. United States
8.4.1. Total Diagnosed Prevalent Cases of Heart Failure in the United States
8.4.2. Gender-Specific Cases of Heart Failure in the United States
8.4.3. Ejection Fraction-Specific Cases of Heart Failure in the United States
8.4.4. Nyha Class-Specific Cases of Heart Failure in the United States
8.4.5. Type-Specific Cases of Heart Failure in the United States
8.4.6. Age-Specific Cases of Heart Failure in the United States
8.5. EU4 and the UK
8.5.1. Total Diagnosed Prevalent Cases of Heart Failure in EU4 and the UK
8.5.2. Gender-Specific Cases of Heart Failure in EU4 and the UK
8.5.3. Ejection Fraction-Specific Cases of Heart Failure in EU4 and the UK
8.5.4. Nyha Class-Specific Cases of Heart Failure in EU4 and the UK
8.5.5. Type-Specific Cases of Heart Failure in EU4 and the UK
8.5.6. Age-Specific Cases of Heart Failure in EU4 and the UK
8.6. Japan
8.6.1. Total Diagnosed Prevalent Cases of Heart Failure in Japan
8.6.2. Gender-Specific Cases of Heart Failure in Japan
8.6.3. Ejection Fraction-Specific Cases of Heart Failure in Japan
8.6.4. Nyha Class-Specific Cases of Heart Failure in Japan
8.6.5. Type-Specific Cases of Heart Failure in Japan
8.6.6. Age-Specific Cases of Heart Failure in Japan
9. Appendix
For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

MENAFN27112024004107003653ID1108932756